Atara Biotherapeutics is a biotechnology company that develops treatments for cancer and other serious diseases. The company's focus is on developing T-cell immunotherapies that harness the power of the immune system to fight cancer. Atara's lead product candidate is tabelecleucel, a T-cell immunotherapy for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. The company was founded in 2012 and is headquartered in South San Francisco, California.